Researchers at ORNL used quantum optics to advance state-of-the-art microscopy and illuminate a path to detecting material properties with greater sensitivity than is possible with traditional tools.
Horizon31, LLC has exclusively licensed a novel communication system that allows users to reliably operate unmanned vehicles such as drones from anywhere in the world using only an internet connection.
A team led by Dan Jacobson of Oak Ridge National Laboratory used the Summit supercomputer at ORNL to analyze genes from cells in the lung fluid of nine COVID-19 patients compared with 40 control patients.
Five researchers at the Department of Energy’s Oak Ridge National Laboratory have been named ORNL Corporate Fellows in recognition of significant career accomplishments and continued leadership in their scientific fields.
A team of researchers has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease — the enzyme that enables the virus to reproduce.
For the second year in a row, a team from the Department of Energy’s Oak Ridge and Los Alamos national laboratories led a demonstration hosted by EPB, a community-based utility and telecommunications company serving Chattanooga, Tennessee.
A joint research team from Google Inc., NASA Ames Research Center, and the Department of Energy’s Oak Ridge National Laboratory has demonstrated that a quantum computer can outperform a classical computer
IDEMIA Identity & Security USA has licensed an advanced optical array developed at Oak Ridge National Laboratory. The portable technology can be used to help identify individuals in challenging outdoor conditions.
OAK RIDGE, Tenn., May 7, 2019—Energy Secretary Rick Perry, Congressman Chuck Fleischmann and lab officials today broke ground on a multipurpose research facility that will provide state-of-the-art laboratory space
OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.